Autopsy report · NCT03234153

Neoadjuvant Immunotherapy With Durvalumab and Tremelimumab for Bladder Cancer Patients Ineligible for Cisplatin

Cause of deathSlow enrollment Automatic label, confidence 0.9, unverified. How labels are made.

“low accrual”

The sponsor’s own words in the registry.

Life of this trial

Registered 1 year before it started.
Ran for about 1 year 10 months before it stopped.
6 participants enrolled.
No results are posted on the registry.

Vital statistics

Status: Terminated
Phase: Phase 2
Sponsor: Insel Gruppe AG, University Hospital Bern
Sponsor type: University, hospital or other
Conditions: Muscle-invasive Bladder Cancer
Interventions: Durvalumab (Imfinzi); Tremelimumab
Participants: 6
Sites: 1
Countries: Switzerland

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.